Overview

Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers

Status:
Completed
Trial end date:
2010-05-07
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of different dose levels of glyburide for injection, administered as a bolus dose followed by a 3-day continuous infusion. The secondary objectives are to assess the pharmacokinetics (PK) of glyburide and blood glucose and serum insulin pharmacodynamic (PD) responses to glyburide.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Remedy Pharmaceuticals, Inc.
Treatments:
Glyburide